Vanguard Group
PBYI icon

Vanguard Group’s Puma Biotechnology PBYI Stock Holding History

Vanguard Group’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$22.6M Buy
3,797,748
+106,028
+3% +$563K ﹤0.01% 2559
2025
Q3 		$19.6M Sell
3,691,720
-14,732
-0.4% -$62.5K ﹤0.01% 2638
2025
Q2 		$12.7M Buy
3,706,452
+37,189
+1% +$119K ﹤0.01% 2778
2025
Q1 		$10.9M Buy
3,669,263
+25,841
+0.7% +$80.9K ﹤0.01% 2802
2024
Q4 		$11.1M Buy
3,643,422
+7,231
+0.2% +$21K ﹤0.01% 2893
2024
Q3 		$9.27M Buy
3,636,191
+37,218
+1% +$113K ﹤0.01% 2996
2024
Q2 		$11.7M Buy
3,598,973
+107,724
+3% +$473K ﹤0.01% 2823
2024
Q1 		$18.5M Sell
3,491,249
-310,832
-8% -$1.67M ﹤0.01% 2644
2023
Q4 		$16.5M Buy
3,802,081
+29,688
+0.8% +$98.4K ﹤0.01% 2683
2023
Q3 		$9.92M Buy
3,772,393
+8,262
+0.2% +$28.1K ﹤0.01% 2885
2023
Q2 		$13.3M Sell
3,764,131
-7,214
-0.2% -$22.5K ﹤0.01% 2790
2023
Q1 		$11.7M Buy
3,771,345
+182,423
+5% +$688K ﹤0.01% 2855
2022
Q4 		$15.2M Sell
3,588,922
-34,707
-1% -$120K ﹤0.01% 2759
2022
Q3 		$8.59M Sell
3,623,629
-7,800
-0.2% -$22.8K ﹤0.01% 3028
2022
Q2 		$10.3M Buy
3,631,429
+164,589
+5% +$409K ﹤0.01% 2974
2022
Q1 		$9.98M Sell
3,466,840
-213,347
-6% -$552K ﹤0.01% 3154
2021
Q4 		$11.2M Buy
3,680,187
+50,754
+1% +$220K ﹤0.01% 3146
2021
Q3 		$25.4M Buy
3,629,433
+43,390
+1% +$325K ﹤0.01% 2716
2021
Q2 		$32.9M Buy
3,586,043
+47,588
+1% +$482K ﹤0.01% 2582
2021
Q1 		$34.4M Buy
3,538,455
+141,766
+4% +$1.58M ﹤0.01% 2511
2020
Q4 		$34.9M Sell
3,396,689
-77,107
-2% -$781K ﹤0.01% 2377
2020
Q3 		$35M Sell
3,473,796
-852,192
-20% -$8.68M ﹤0.01% 2196
2020
Q2 		$45.1M Sell
4,325,988
-308,709
-7% -$3.2M ﹤0.01% 2058
2020
Q1 		$39.1M Buy
4,634,697
+648,571
+16% +$6.3M ﹤0.01% 1982
2019
Q4 		$34.9M Buy
3,986,126
+490,422
+14% +$4.06M ﹤0.01% 2278
2019
Q3 		$37.6M Buy
3,495,704
+430,025
+14% +$4.64M ﹤0.01% 2199
2019
Q2 		$39M Buy
3,065,679
+118,785
+4% +$2.74M ﹤0.01% 2230
2019
Q1 		$114M Buy
2,946,894
+152,157
+5% +$4.65M ﹤0.01% 1682
2018
Q4 		$56.9M Sell
2,794,737
-24,381
-0.9% -$732K ﹤0.01% 1960
2018
Q3 		$129M Buy
2,819,118
+85,319
+3% +$4.11M 0.01% 1668
2018
Q2 		$162M Buy
2,733,799
+84,000
+3% +$4.87M 0.01% 1493
2018
Q1 		$180M Buy
2,649,799
+34,730
+1% +$2.6M 0.01% 1350
2017
Q4 		$259M Buy
2,615,069
+65,841
+3% +$7.37M 0.01% 1125
2017
Q3 		$305M Buy
2,549,228
+74,584
+3% +$6.94M 0.01% 990
2017
Q2 		$216M Buy
2,474,644
+45,735
+2% +$2.56M 0.01% 1183
2017
Q1 		$90.4M Buy
2,428,909
+101,722
+4% +$3.71M ﹤0.01% 1709
2016
Q4 		$71.4M Buy
2,327,187
+323,201
+16% +$14M ﹤0.01% 1799
2016
Q3 		$134M Buy
2,003,986
+74,579
+4% +$3.77M 0.01% 1388
2016
Q2 		$57.5M Buy
1,929,407
+95,570
+5% +$2.99M ﹤0.01% 1836
2016
Q1 		$53.9M Buy
1,833,837
+44,725
+2% +$2.02M ﹤0.01% 1832
2015
Q4 		$140M Buy
1,789,112
+14,139
+0.8% +$1.11M 0.01% 1230
2015
Q3 		$134M Buy
1,774,973
+24,932
+1% +$2.36M 0.01% 1234
2015
Q2 		$204M Buy
1,750,041
+90,443
+5% +$16.4M 0.01% 1042
2015
Q1 		$392M Buy
1,659,598
+136,483
+9% +$29.2M 0.03% 697
2014
Q4 		$288M Buy
1,523,115
+21,899
+1% +$4.86M 0.02% 776
2014
Q3 		$358M Buy
1,501,216
+9,043
+0.6% +$1.86M 0.03% 654
2014
Q2 		$98.5M Buy
1,492,173
+1,479
+0.1% +$105K 0.01% 1408
2014
Q1 		$155M Buy
1,490,694
+163,656
+12% +$19.2M 0.01% 1070
2013
Q4 		$137M Buy
1,327,038
+99,778
+8% +$5.86M 0.01% 1111
2013
Q3 		$65.9M Buy
1,227,260
+190,873
+18% +$10.3M 0.01% 1534
2013
Q2 		$46M Buy
+1,036,387
New +$36.5M ﹤0.01% 1678

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $20.1B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Vanguard Group's PBYI Position: Q4 2025 in Review

Vanguard Group increased its Puma Biotechnology (PBYI) stake by 2.9% in Q4 2025, buying an estimated $563K and bringing the position to 3,797,748 shares worth $22.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2559.

Vanguard Group first reported a position in PBYI in Q2 2013 and has held it in 51 quarters since. The position peaked at $392M in Q1 2015. 151 funds tracked by Wall St. Rank hold PBYI as of Q4 2025.

  • Vanguard Group held 3,797,748 shares of Puma Biotechnology worth $22.6M as of Q4 2025.
  • Vanguard Group bought 106,028 Puma Biotechnology shares in Q4 2025, an estimated $563K.
  • Puma Biotechnology made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2559 holding.
  • Vanguard Group first reported a position in Puma Biotechnology in Q2 2013 and has held it in 51 quarters since.
  • Vanguard Group's Puma Biotechnology position peaked at $392M in Q1 2015.
  • 151 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.